Skip to main content
Figure 2 | BMC Cancer

Figure 2

From: The SystHERs registry: an observational cohort study of treatment patterns and outcomes in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer

Figure 2

Patient flow through the SystHERs registry at baseline. BC, breast cancer; CRFs, case report form; de novo disease, previously undiagnosed metastatic breast cancer; ECOG PS, Eastern Cooperative Oncology Group performance status; HER2, human epidermal growth factor receptor 2; recurrent disease, first detection of metastases >90 days following histological diagnosis of early-stage breast cancer; SystHERs, Systematic Therapies for HER2-positive Metastatic Breast Cancer Study; TNM, tumor–node–metastasis.

Back to article page
\